NeoStem, Inc. and RimAsia Capital Partners, a Prestigious Asian Private Equity Firm, Complete Financing
The financing consists of units priced at $1.25 per unit with each unitconsisting of one share of common stock and a warrant to purchase one share ofcommon stock at $1.75.
Dr. Robin Smith, Chairman and CEO of NeoStem stated, "We are thrilled tohave an investment from a fund that operates in partnership with a regionalnetwork of strategic investors drawn from leading Asian families andcompanies. With extensive investment expertise and experience, RimAsiainvests in businesses with strong prospects that could benefit from itscapital and guidance. We believe this investment from RimAsia is the firststep in our gaining exposure in the global markets, furthers our plans forexpansion overseas and opens the door to future acquisition targets."
Dr. Smith further commented, "As we transition from an early stage companyto one which is focused on generating revenue, we intend to place emphasis ona national marketing, public relations and sales campaign to alert the mediaand general public as to the importance of collecting and storing their ownadult stem cells. An important part of this program will involve Companyspokesperson Suzanne Somers who writes about the Company in her new book"Breakthrough: Eight Steps to Wellness" being released this month.
Asia has been a leading example to the world as to the importance andefficacy of stem cell therapy and other breakthrough medical advancements.More and more individuals have been traveling outside the United States toreceive stem cell treatment for various illnesses and diseases.
RimAsia's portfolio companies include investments in PRC companies thatare engaged in pharmaceutical manufacturing, drug delivery systems, coalblending, print media and semiconductor design.
Eric Wei, Managing Partner of RimAsia Capital Partners, said, "We areextremely excited by the growth prospects for NeoStem, particularly thedevelopment of the Company's very small embryonic-like (VSEL) stem celltechnology which we believe one day could be the non-embryonic stem cellsolution to treating many diseases that affect people worldwide. We believethere is strong potential for collaborating with NeoStem in introducing theVSEL technology to the PRC market, as well as commercializing a number of theother current businesses of the Company in China.
The securities sold were sold without registration under the SecuritiesAct of 1933, as amended (the "Act") pursuant to Regulation S promulgated underthe Act and may not be resold in the United States or to U.S. persons unlessregistered under the Act or pursuant to an exemption from registration underthe Act. Hedging transactions involving such securities may not be conductedunless in compliance with the Act.
About NeoStem, Inc.
NeoStem is managing a network of adult stem cell collection centers inmajor metropolitan areas in the United States, enabling people to donate andstore their own (autologous) stem cells when they are young and healthy fortheir personal use in times of future medical need. The Company also hasentered into research and development through the acquisition of a worldwideexclusive license of technology to identify and isolate VSEL(very smallembryonic-like) stem cells, which have been shown to have several physicalcharacteristics that are generally found in embryonic stem cells.
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995, including, withoutlimitation, statements regarding potential collaboration between NeoStem andRimAsia or other parties. Forward-looking statements reflect management'scurrent expectations, as
You May Also Like